Matching Heterogeneous Cohorts by Projected Principal Components Reveals Two

Novel Alzheimer's Disease-Associated Genes in the Hispanic Population

Julian Daniel Sunday Willett[1], Mohamad Waqas[1], Serhiy Naumenko[2,3], Kristina Mullin[1],

Julian Hecker[4], Lars Bertram[5], Christoph Lange[2], Ioannis Vlachos[6], Winston Hide[6],

Rudolph E. Tanzi[1c], Dmitry Prokopenko[1c].

c: Correspondence: rtanzi@mgh.harvard.edu (RET); dprokopenko@mgh.harvard.edu
(DP)

Affiliations:

1.   Genetics and Aging Unit and McCance Center for Brain Health, Department of
     Neurology, Massachusetts General Hospital, Boston, MA.

2. Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston,
   Massachusetts, USA

3. Newborn Screening Ontario, Ottawa, Ontario, Canada

4. Channing Division of Network Medicine, Brigham and Women's Hospital, Boston,
   MA, USA

5. Lübeck Interdisciplinary Platform for Genome Analytics, Institutes of Neurogenetics and Cardiogenetics, University of Lübeck, Lübeck, Germany

6. Department of Pathology, Beth Israel Deaconess Medical Center, Boston, MA, USA

Abstract

Alzheimer's disease (AD) is the most common form of dementia in elderly, affecting 6.9 million individuals in the United States. Some studies have suggested the prevalence of AD is greater in individuals who self-identify as Hispanic. Focused results are relevant for personalized and equitable clinical interventions. Ethnicity as a stratifying tool in genetic studies is often accompanied by genomic inflation due to heterogeneity. In this study, we report GWAS and meta-analyses conducted among NIAGADS subjects who self-identified as Hispanic and All of Us (AoU) sub-cohorts matched to that cohort, using projected genetically-derived principal components, with and without age and sex. In Hispanic NIAGADS subjects, we identified a common variant in *PIEZO2* that was protective for AD with a p-value just beyond genome-wide significance (p = $5.4 * 10^{-8}$). Meta-analyses with genetically-matched AoU participants yielded three (two novel) genome-wide significant AD-associated loci based on rare lead variants: rs374043832 (*RGS6/PSEN1*), rs192423465 (*ASPSCR1*), and rs935208076 (*GDAP2*), which were also nominally significant in AoU sub-cohorts. We thus demonstrate an efficient way to select subjects from large heterogeneous biobank cohorts who are genetically similar to a smaller disease-specific cohort, yielding novel disease-relevant findings.

Introduction

Alzheimer's disease (AD) is a high-morbidity illness predicted to affect 13.8 million individuals in the United States by 2050[1]. While studies have revealed meaningful disease-relevant genes[2,3], fewer studies have clarified its genetic determinants in groups beyond those of European ancestry. AD has been observed to be more prevalent in Latinos with several genes linked to familial AD risk in this group, including *PSEN1* and *BIN1*[4]. Polygenic risk score calculations for Hispanic participants have found APOE alleles to be useful in predicting mild cognitive impairment[5]. A GWAS was conducted on the Hispanic Community Health Study in 2021, identifying a novel variant with association with mild cognitive impairment[6].

Ethnicity is an imperfect stratifier in genetics studies due to the additional diversity it can fail to capture. Beyond the National Academies releasing a report in 2023 acknowledging the limitations of social-constructed subgroup analyses in genetics[7], individuals who identify as Hispanic are incredibly diverse with significant genetic variation across communities[8], contributed to by historical migration and admixture[9,10]. This heterogeneity, which can produce genomic inflation and reduce confidence in results, is not unexpected considering that ethnicity captures fewer generations of one's family history than genetic ancestry, which groups individuals by the predicted geographic distribution of one's ancestors from millennia before. Ethnicity as a stratifier remains common in AD genetics studies[11,12], perhaps driven by efforts to yield results that can generalize to individuals of diverse backgrounds. This complicates efforts to combine different studies of Hispanic subjects together in a meta-analysis, given possible heterogeneity.

In this study, we aimed to develop a means of studying AD across populations that are historically heterogeneous. We performed a genome-wide association study (GWAS) in a Latino population from NIAGADS with clinical AD and sought to replicate the findings in a large population-based cohort from All of Us (AoU) with an AD-by-proxy phenotype. Combining concepts underlying population genetics and clinical trials, we matched NIAGADS participants who self-identified as Hispanic to participants in AoU using genetically derived principal components, after projecting subjects in AoU onto our NIAGADS sub-cohort PC space. We then ran GWAS on each subgroup and meta-analyzed the results, identifying two novel rare loci associated with AD nominally significant in both sub-cohorts, alongside *APOE* (**Figure 1**). We identified two novel rare AD-associated loci and show how population stratification can be controlled in studies with diverse participants while maximizing power and yielding more generalizable results. We also demonstrate an efficient way to select subjects from a large biobank cohort who are genetically similar to a disease-based cohort.

Results

Sample, Variant-Level Quality Control and Genetic Matching.

For NIAGADS, we isolated genetic data for a cohort of individuals self-reporting Hispanic ethnicity. We removed technical replicates, individuals missing an AD diagnosis, related individuals, samples with a high missingness rate, outliers based on principal components, and variants that were outliers based on HET/HOM ratio. This resulted in 38,989,734 variants and 8,467 samples.

Next, we calculated "reference" PCs on our NIAGADS sub-cohort, using a set of LD-pruned common variants present in NIAGADS and All of Us (AoU). We projected AoU PCs onto the reference PCs and used both PC sets to select subjects from AoU which genetically matched our discovery dataset. We created two matching cohorts using subclassification models: the first, matched solely on PCs and Affection Status, the second, also accounting for age and sex. The genetic data for each AoU sub-cohort was then filtered for flagged samples or variants and variants with excessive missingness. This left 49,511,921 variants and 44,793 samples in the AoU sub-cohort, matched by solely projected PCs and 40,635,522 variants and 25,502 samples in the AoU sub-cohort, matched by projected PCs, age, and sex (**Supplemental Table 1**).

For the meta-analysis, matching AoU participants to NIAGADS participants who self-identified as Hispanic increased the case count five-fold when matching with genetic PCs, and almost three-fold when matching with genetic PCs, age, and sex (**Supplemental Table 1**). Including age and sex as covariates yielded an AoU matched participant age distribution more closely resembling NIAGADS with minimal effect on the proportion reporting female sex (**Figure 2**). The distribution of genetic ancestries varied dramatically between NIAGADS participants who self-identified as Hispanic and the matched AoU participants (**Supplemental Table 1 and Supplemental Figure 2**). Individuals who self-identified as Hispanic in NIAGADS were predominantly predicted to have European genetic ancestry with AoU predominantly composed of participants predicted to have admixed American genetic ancestry (**Supplemental Table 1**). Most AD-by-proxy cases in the AoU sub-cohorts were predicted to have European genetic ancestry, similarly to NIAGADS (**Supplemental Table 1**).

We identified 3 loci with variants beyond or close to genome-wide significance for NIAGADS participants who self-identified as Hispanic, with the study having minimal evidence of genomic inflation ($\lambda = 1.00$) (**Figure 3A, Supplemental Figure 1A**). The first locus was at *APOE*, with the lead variant p-value of $3.2 * 10^{-46}$. The second locus within the *ZFYVE1* gene, encoding Zinc Finger FYVE Domain-containing Protein 1, resides 138 kb from the early-onset familial AD gene, presenilin 1 (*PSEN1*), and the lead variant had a genome-wide significant p-value of $6.7 * 10^{-10}$ (**Table 1**). The *ZFYVE1* locus most likely represents the *PSEN1* haplotype from Caribbean Hispanics[13], observed in a prior NIAGADS release[14].   The third novel locus was at the gene encoding Piezo-Type Mechanosensitive Ion Channel Component 2 (*PIEZO2*), and the lead common variant was protective against AD with a p-value just beyond genome-wide significance (p = $5.4 * 10^{-8}$) (**Table 1**). *PIEZO2* encodes the pore-forming subunit of the mechanosensitive cation Piezo channel, which is required for mechanically activated currents with roles in sensing touch and tactile pain[15]. *PIEZO2* has homology to *PIEZO1*[16], which has been previously linked to amyloid beta clearance[17].

All of Us Participants Matched to NIAGADS GWAS.

We next performed a GWAS in a genetically matched cohort from AoU, where genetic matching was performed with and without age and sex covariates. Lambda values for genomic inflation for both AoU GWAS were below 1.0 (**Supplemental Figure 1**). The *APOE* locus yielded a p-value of $2.3 * 10^{-7}$ in AoU when including age and sex in the matching schema, and a less significant p-value (p=0.0007) when matching solely

on genetic PCs. (**Table 1**). For AoU participants matched with solely PCs, the GWAS

yielded 8 novel loci (1 common, 7 rare), which were proximal to the gene encoding the

Spen Family Transcriptional Repressor (*SPEN)*, long intergenic non-protein coding

RNA 1364 (*LINC01364*), 5S Ribosomal Pseudogene 533 (*RNA5SP533*), Secretion

Associated Ras Related GTPase 1B (*SAR1B*), Olfactory Receptor Family 4 Subfamily A

Member 5/ Tripartite Motif Containing 48 (*OR4A5*/*TRIM48*), RNA, 7SL, cytoplasmic 33,

pseudogene/ Platelet Activating Factor Acetylhydrolase 1b Regulatory Subunit 1

(*RN7SL33P*/*PAFAH1B1*), Unk Zinc Finger (*UNK*), and Erythrocyte

Membrane Protein Band 4.1 Like 1) (*EPB41L1*) (**Figure 3**, **Table 1**). The genome-wide

significant lead variants from AoU were either not detected or not significant (**Table 1**).

For AoU participants matched by PCs, age, and sex, a smaller cohort, we identified five

new loci (1 common, 4 rare), of which two were also genome-wide significant in the AoU

cohort matched by purely PCs. These loci were proximal to *SPEN*, Microtubule Actin

Crosslinking Factor 1 (*MACF1*), *RNA5SP533*, Ral GEF with PH domain and SH3

binding motif 2 (*RALGPS2*), and *OR4A5*/*TRIM48* (**Figure 3**, **Table 1**). While there was

extensive overlap of subjects in the two AoU sub-cohorts, each lead variant was

nominally significant in the other (**Table 1**).

Focusing on the genes that were genome-wide significant in both AoU sub-

cohorts, *SPEN* contains a lead, rare variant predicted to increase AD risk in both AoU

sub-cohorts. *SPEN* is enriched in brain and plays a role in regulating gene transcription,

believed mediated by hormonal signaling[15]. *SPEN* has not been previously linked to

dementia, but haploinsufficiency in the gene has been linked to intellectual disability and

brain anomalies, particularly in females[18]. *RNA5SP533*, a gene 230 kb from the lead

variant in a common variant predicted to increase AD risk, is a ribosomal pseudogene[19], with variants previously linked to breast cancer and anxiety[20]. Copy-number variants proximal to the olfactory gene, *OR4A5*[15], have been associated with amyotrophic lateral sclerosis[21]. Finally, *TRIM48* plays a role in cell death related to oxidative stress, and a prior study has linked the gene to AD when studying individuals in extreme quantiles of an AD PRS[22], a method that some believe increases the risk of false positives[23].

Meta-analyses of NIAGADS Sub-cohort and Matched AoU Participants.

We next carried out a meta-analysis of the results from our NIAGADS sub-cohort with each matched AoU subpopulation. Genomic inflation remained controlled, with inflation factors less than 1 (**Supplemental Figure 1**). To focus on generalizable results, we focused on variants observed in both studies. This excluded the genome-significant loci we observed in the AoU GWAS, while yielding additional novel loci in each AoU sub-cohort that were also nominally significant in our NIAGADS sub-cohort. For a rare variant with a MAF of 0.001, 0.003 and 0.005 and a combined sample size of 53,260 (n_{cases}=12,038, AoU matched by genetic PCs), we had at least 80% power to identify variants with a genotype relative risk (GRR) of 2.64, 1.81 and 1.59, respectively. If we used a combined sample size of 33,969 (n_{cases}=7,192, AoU matched by genetic PCs, age and sex), the range of GRRs was 3.36, 2.11 and 1.81.

In both meta-analyses, the *APOE* locus was reproduced with supporting statistics across studies (**Figure 4, Table 2**). In addition, a rare variant in Regulator Of G Protein Signaling 6 (*RGS6)*, appeared in both meta-analyses, however it was in LD and < 1 Mb from PSEN1 mutations. In both meta-analyses, rs374043832 near *RGS6*, had a p-value

just beyond nominal significance (p = 0.051 and p = 0.051) in the AoU analyses (**Table 2**). We also identified two novel variants in the meta-analysis employing AoU participants matched by genetic PCs, all rare, proximal to UBX Domain Containing Tether For SLC2A4 (*ASPSCR1*), and Erythrocyte Membrane Protein Band 4.1 Like 1 (*EPB41L1*) (**Table 2**), with the locus proximal to *ASPSCR1* being nominally significant in both NIAGADS and AoU (**Table 2**). This variant was present in 24/9479 cases (with one affected carrier being homozygous) and 193/35314 controls in AoU (matched by genetic PCs) and 23/2559 cases and 23/5908 controls in our NIAGADS cohort. We also observed one rare novel loci in the meta-analysis employing AoU participants matched by genetic PCs, age, and sex, proximal to Small nucleolar RNA SNORA40/Ganglioside Induced Differentiation Associated Protein 2 (*RF00561/GDAP2*) (**Table 2**). The locus proximal to *GDAP2* was nominally significant in NIAGADS and the AoU sub-cohort (**Table 2**). This variant was present in <20/4633 cases and 37/20869 controls in AoU (matched by genetic PCs, age, and sex) and 15/2559 cases and 15/5908 controls in NIAGADS. These loci, which were nominally significant, or nearly nominally significant, in both studies will be referred to as "higher confidence loci" (all loci except *EPB41L1*).

   ASPSCR1, which contains an intronic variant in the mutually nominally significant locus, is enriched among pathways with roles in brain immune response and modulates glucose transport by interactions with Glucose Transporter Type 4 (GLUT4)[15]. This gene has been previously observed to be significantly less expressed in individuals with AD from data contained in the Gene Expression Omnibus database[24]. *GDAP2*, which is roughly 50 kb from a rare locus that was mutually nominally significant, is enriched among gene pathways with roles in transcription, previously implicated in

spinocerebellar ataxia 27[15], which includes dementia-like phenotypes[25]. *RGS6*, which contains an intronic variant in the nearly mutually nominally significant locus, is enriched among mixed processes in neurons, including neuronal signaling in single cells[15]. It displays enriched expression in excitatory and inhibitory neurons as well as astrocytes with roles involving inhibition of signal transduction through GTPase pathways[15]. RGS6 has been previously linked Parkinson disease[26].

Reproduction of Loci that were Nominally Significant in Both Datasets in Broader Cohorts.

Having matched AoU participants by genetic and phenotypic similarity to our NIAGADS sub-cohort, we next set out to determine whether the results could be generalized to broader populations. We evaluated our higher confidence loci in our prior AoU study including all participants[27], all AoU participants with admixed American genetic ancestry, AoU participants not in the matched cohorts, and in NIAGADS when studying all participants (**Supplemental Table 2**). We also attempted validation of our genome-wide significant variants in the Massachusetts General Brigham biobank, UK Biobank, and the newest release of NIAGADS after excluding participants we used in this study. We studied all these NIAGADS participants, also studying subcohorts, including new participants who identified as Hispanic and those with African, admixed American, and European genetic ancestry (**Supplemental Table 2**). All variants were nominally significant in the all-participant AoU GWAS, with only rs374043832 in *RGS6* being nominally significant in the all-participant NIAGADS study (**Supplemental Table 3**). When we evaluated variants for association with AD-by-proxy in AoU participants,

who were not matched to the NIAGADS sub-cohort, only rs192423465 in *ASPSCR1*, was reproduced, but limited to AoU participants who did not meet the threshold for being matched to the NIAGADS sub-cohort when employing genetic PCs, age, and sex (**Supplemental Table 3**). There were 1,811 AD-by-proxy cases in AoU participants that did not meet the threshold for matching by solely genetic PCs and 7,044 cases for participants who did not meet matching criteria by genetic PCs, age, and sex. Aside from rs374043832 (*RGS6*) in AoU participants who were logged as having admixed American genetic ancestry, these variants were not significant or detected when we evaluated other populations, including AoU participants with Admixed American or African genetic ancestry, UK Biobank, or African American and Asian NIAGADS participants[27]. Several of our novel variants were validated in other independent cohorts, including rs4573993 in *PIEZO2* in MGB Biobank with matching effect direction (p = 0.006) and rs889400412 in *RALGPS2* in the updated NIAGADS cohort after excluding this study's participants in the all participants cohort (p = 0.04) and European genetic ancestry cohort with matching effect direction (p = 0.006) (**Supplemental Table 3**). We found that several of the hits we identified that were already known were validated with rs374043832 in *RGS6/PSEN1* associated with AD in the new NIAGADS release's Hispanic participants after excluding those in this study with matching effect direction (p = 0.001) and admixed American NIAGADS participants (p = 0.009) (**Supplemental Table 3**). rs192423465 in *ASPSCR1* in the updated NIAGADS Hispanic participant cohort after excluding this study's participants had an opposite effect direction with nominal significance (p = 0.04) and rs182804071 in *ZFYVE1* in NIAGADS

Differential Gene Expression of Genes Proximal to Novel Loci.

To further clarify the role of the genes proximal to our higher confidence loci, we used data from gene differential expression in brain single-cell populations for individuals with and without AD and pathological hallmarks of AD[28]. *ASPSCR1* was significantly less expressed in excitatory neurons when comparing individuals with pathological hallmarks of AD to those with and without cognitive impairment or comparing groups 3 and 4 (**Table 3**). *GDAP2* was significantly more expressed in excitatory neurons in individuals with pathological evidence of AD as compared to individuals without such evidence (**Table 3**).

We next evaluated these associations in additional analyses available from Mathys et al. 2023, which evaluated differential gene expression by severity of cognitive impairment, accounting for the extent of AD-characteristic pathological hallmark. In these studies, more excitatory neuron subpopulations demonstrated differential gene expression according to pathological features (**Table 4**)[28]. While *ASPSCR1* was significantly less expressed in individuals with no to mild to severe cognitive impairment in the setting of general AD pathology (group 1 vs 2 vs 3), eight subpopulations of excitatory neurons were downregulated in participants with mild cognitive impairment versus none when considering one's amyloid burden and six subpopulations when considering neuritic plaque burden (**Table 4**). *GDAP2* was significantly upregulated

across diverse pathological hallmarks when comparing by degree of cognitive impairment (**Table 4**).

Discussion

In this study, we demonstrated how one can identify novel disease loci by matching subjects from smaller disease-focused cohorts to large biobanks while controlling for bias and population stratification, even for populations that are historically diverse. Projecting genetic data and matching participants by genetic PCs, we reproduced known AD loci and discovered new loci. The *APOE* SNP rs429358 was genome-wide significant in NIAGADS, however in AoU it showed less significant p-values, when subjects were matched by genetic PCs, age, and sex (p = $2.3 * 10^{-7}$), or by genetic PCs only (p = $7.3 * 10^{-4}$). This could be attributed to the potential noisiness of the less than optimal AD-by-proxy phenotype, especially for younger subjects[27]. When age and sex were added to the matching covariates, older AoU subjects were selected and the *APOE* signal became more pronounced. In NIAGADS, we also identified a novel association of AD with a variant in *PIEZO2*, which was protective with a p-value just beyond genome-wide significance (p = $5.4 * 10^{-8}$). *PIEZO2* is a homolog of *PIEZO1*, which has previously been shown to influence clearance of Aβ[15].

Meta-analyses yielded two novel rare loci, with lead variants rs192423465 (*ASPSCR1*), and rs935208076 (*GDAP2*) that were nominally significant in both cohorts and the broader AoU population (**Table 2**). rs192423465 was also reproduced in AoU participants who failed to meet inclusionary criteria when matching by genetic PCs, age,

and sex (**Supplemental Table 3**). The genomic inflation factor for these meta-analyses were less than 1.

ASPSCR1 and GDAP2 have been linked to other neurodegenerative disorders with pathogenic mechanisms relevant to AD. ASPSCR1 has been previously linked to amyotrophic lateral sclerosis and inclusion body myopathy with early-onset Paget disease and frontotemporal dementia[29]. ASPSCR1 plays a role in intracellular protein transport and, in particular, glucose homeostasis and transport. ASPSCR1 is a chaperone protein that serves to mitigate protein aggregation and misfolding. Future studies are needed to assess whether ASPSCR1 affects aggregation of hyper-phosphorylated tau and amyloid beta[30]. GDAP2 mutations have been observed in individuals with autosomal recessive cerebellar ataxia, specifically spinocerebellar ataxia type 27, which may present with progressive spasticity and dementia[25]. This gene normally plays a role in cellular response to stress, lysosomal function, retinoic acid response, cerebral cortical atrophy, hippocampal excitatory synaptic activity, and has been linked to gliosis, a key feature of AD[19,31,32] . Finally, RGS6 (near PSEN1), acts as a GTPase-activating protein and plays roles in cellular signaling and regulation. RGS6 has been previously associated with Parkinson disease[26].

With regard to limitations of this study, we note that AD-by-proxy is used to determine affection status in the AoU biobank, with limited subjects diagnosed by clinical AD. Although the AD-by-proxy definition can potentially introduce biases[33], it has been strongly correlated with AD status and increases statistical power, especially in population-based biobanks[34]. Its results, particularly in AoU, must be carefully curated and evaluated, as we demonstrated in a prior manuscript[27]. Here, we aimed to mitigate

possible bias by initially focusing on signals that were nominally significant with clinical AD from NIAGADS. While we considered participants with first-degree relatives with AD or grandparents with AD, the latter being 25% genetically similar to the participant versus the 50% of first-degree relatives, we used this definition given precedents set by other studies[35,36]. Future validation studies of identified signals in other large Latino cohorts with clinical AD are warranted. We also note that we did not analyze sex chromosomes. The locus at *RGS6* is proximal to *PSEN1*, being less than 1 Mb away from rs63750082 (p.Gly206Ala). The rare variants shared most of the carriers in NIAGADS although showing modest LD (D' = 0.1). While we emphasized variants that were genome-wide significant and nominal in both of our datasets while implementing quality control to focus on variants present in an adequate number of participants, with power calculations suggesting adequate power, they were rare variants with results that could be susceptible to bias. Some of these results, both from GWAS and meta-analysis, were also not validated on additional independent cohorts, which underscores the role of cohort on generalization of results.

Conclusion

In meta-analyses matching subjects from smaller disease-focused cohorts to large biobanks, while controlling for bias and population stratification, we identified two novel loci associated with AD, *ASPSCR1* and *GDAP2*, all driven by rare variants. In addition, in NIAGADS subjects who self-identified as Hispanic, we identified a common variant in (*PIEZO2*), that was protective for AD with a p-value just beyond genome-wide

significance (p = $5.4 * 10^{-8}$). Importantly, we show that population stratification in heterogeneous populations can be mitigated in meta-analyses by matching participants using projected principal components, enabling the use of large, multiethnic, and, importantly, diverse biobank cohorts in combination with smaller disease-specific cohorts.

Methods:

Cohorts:

The NIAGADS dataset includes harmonized phenotypes and sequencing data from cohorts sequenced by the Alzheimer's Disease Sequencing Project and other AD and Related Dementia's studies. Full details can be found on NIAGADS (https://dss.niagads.org/datasets/ng00067/) and elsewhere[37]. The NG00067.v9 release was used for this paper, which included 26,243 participants with an AD diagnosis. In addition, we used NG0067.v14 for validation in subjects, which were not included in the v9 release. The All of Us (AoU) cohort studies traditionally underrepresented individuals in biomedical research from the United States of America, offering 245,388 individuals' short-read whole genome sequencing calls in release 7 with information from surveys, wearables, physical measurements taken at the time of participant enrollment, and electronic health records (EHRs)[38,39]. The Mass General Brigham (MGB) Biobank (https://biobank.massgeneralbrigham.org/) is a hospital-based research cohort comprising over 135,000 individuals recruited from multiple institutions within the MGB healthcare system, the parent organization of Massachusetts General Hospital and

Brigham and Women's Hospital[40]. All participants in this biobank provided informed consent for biospecimen collection, access to electronic health records (EHRs), and genomic analysis. The cohort includes individuals of diverse ancestries and clinical backgrounds, enabling broad applicability to translational research. Whole Genome Sequencing (WGS) was performed for a subset of participants, including all ICD-10 Alzheimer's disease cases and older control subjects which included a substantial proportion of APOE carriers. WGS was run at the MGB PM Biobank Genomics Core using Illumina TruSeq DNA PCR-Free library construction kit with sequencing using NovaSeq 6000. Variant calling was performed using Illumina's DRAGEN pipeline. The UK Biobank, a long-term study based in the United Kingdom, has gathered an extensive array of healthcare data from 502,357 individuals. This includes short-read whole-genome sequencing data from 200,004 of these participants, which were employed in this study.

Outcomes

In NIAGADS, cases were individuals meeting the NINCDS-ADRDA criteria for definite, probable, or possible AD, had documented age at death (for pathologically verified cases) or age at onset, and ApoE genotyping. Controls were individuals over age 60 and free of dementia. AoU and UKB cases are defined by individuals having an ICD-9 (331.0) or ICD-10 (G30.9) code for AD or history of dementia in a first-degree relative or grandparent. While prior studies have focused on individuals with affected parents for a proxy case[3], with quantitative definitions reportedly limiting bias[41], genetic similarity between any first-degree relative is comparable. Affected grandparents are

minimum 25% genetically similar, with precedent for their inclusion[35,36]. A quantitative definition was not possible in AoU, contrary to in UKB, given that parental age and age of parental death were unavailable[41].

Genetic data quality control.

For NIAGADS, WGS variant calls for biallelic variants in 34,438 individuals were downloaded for the NIAGADS dataset from NG00067.v9 release. We excluded technical replicates, keeping the sample with fewer missing variant calls, those with a missing AD diagnosis, outliers by HET/HOM ratio (6 standard deviations from the mean), subjects with greater than 5% sample missingness, subjects from pairs that were second degree relatives or closer per KING[42] calculations. The final dataset had 26,243 subjects. We focused on individuals who self-identified as Hispanic (n = 8,467), excluding subjects who were outliers based on genetic PCs, having analyzed and meta-analyzed data for the full cohort in a prior paper[27]. In addition, we have used the "bigsnpr" package and followed their vignette (https://privefl.github.io/bigsnpr/articles/ancestry.html#ancestry-grouping) to cluster subjects into groups of predicted genetic ancestry (**Supplemental Table 1**). Briefly, we used a set of reference allele frequencies and corresponding PC loadings provided by this paper[43]. Next, we used Euclidean distance on the PC space to assign a subject to the closest one of the 21 reference groups. We further combined the 21 groups into 5 continental-based groups (reported in Supplemental Table 1).

For replication in the independent subjects from NG00067.v14 release, which were not included in the v9 release, we followed the same protocol as above but

excluded the original self-identified Hispanic subjects. This new-subject-only cohort consisted of 32,377 total individuals, with 3,018 being self-identified Hispanic. We also used the same PC-based grouping method above to categorize the new subjects into three ancestry groups: African (n = 5,748), American (n = 1,652), and European (n = 20,062). were processed similarly.

For AoU, data was processed similarly to Willett et al. 2025[27], which studied AD-by-proxy in AoU and UKB, using processing similar to others[44,45]. Full Hail variant dataset (VDS) files for AoU were filtered for 550 AoU-flagged samples and AoU-flagged variants, leaving 1,085,790,733 variants and 244,845 samples. We removed variants with more than 10% missingness or occurring in fewer than 20 individuals, given data-reporting privacy practices[3,45].

For the UKB data, WGS files were initially converted from their original VCF format to biallelic PGEN format using PLINK2 (with original multiallelic variants being split using bcftools) to make them compatible with subsequent Regenie analysis. The files were filtered for variants with more than 10% missingness, samples with more than 10% missingness, Hardy-Weinberg p-values less than 1×10^{-15}, variants occurring in less than 3 individuals, and spanning deletions[3,45].

For MGB, WGS data on 3,227 individuals were used. We utilized the PC-based clustering method above to group the participants into ancestry categories. We kept only those subjects of European ancestry and were left with 3,142 individuals.

Matching of NIAGADS participants with All of Us participants.

Using the BigSnpR package[46], we imported the raw genetic data for common (MAF $\geq$ 1%) variants meeting HWE and call rate criteria from our NIAGADS sub-cohort and all AoU participants. We then projected the genetic data into a shared space using the "bed_projectPCA" function from the same package, using the NIAGADS sub-cohort as the reference population and outputting the first 20 projected principal components. We obtained the projected PCs for our model using the "predict()" function on the projected results' output's SVD of the reference data for NIAGADS and the online augmentation, decomposition, and Procrustes (OADP) projection results of the model for AoU results. We then produced two models using the R package, MatchIt[47]. We used the first twenty projected PCs alone with AD case status as covariates against cohort as the outcome for the first model (Cohort ~ PCs + AD status). The second model was identical, also including age and sex as covariates. We used a subclassification as our method, computing 500 subclassification groups. Distance was computed using a generalized linear model and the estimand used NIAGADS as the reference group, thus each NIAGADS participant had a weight of 1 in the output model. To select for AoU participants most similar to our NIAGADS sub-cohort, we isolated AoU participants for each model with a weight matching or exceeding the NIAGADS reference weight of 1. Code for this analysis is available in our Code Availability section.

Genome-wide association analysis.

For NIAGADS we performed a logistic regression (with option "firth-fallback") for case/control status as implemented in Plink2, studying individuals of varying sub-

cohorts, which included those self-reporting as Hispanic for this study[48]. We included sex, age, sequencing center, sample set and 5 Jaccard principal components with standardized variance as covariates[49].

For AoU and UKB, Regenie v3.2.8 was used to conduct GWAS[45]. Covariates for the AoU analysis included age of enrollment, sex, and the first twenty principal components (PCs) for members of each tested cohort, determined using Plink2[44,48]. Sequencing center information in AoU was unavailable[38]. Covariates for the UKB analysis included age at enrollment into UKB, sex, the first twenty PCs, and sequencing center[50]. Outcomes were defined, as above. Step 1 was accomplished with array data for participants in each matched subcohort, following similar methodology to another study that worked on AoU, filtering for variants with a MAF $\geq$ 1%, minimum allele count of 100, and variant missingness $\leq$ 10%[44]. This data was then pruned for independent variants using 100 kb windows with a single-base step-size and 0.1 r^2 threshold, with sex chromosomes removed.

Step 2 was accomplished using whole-genome sequencing files, processed as described above, with array-based step 1 predictions. We used Firth penalized regression for variants with p < 0.01 and a minimum minor allele count of 20 for AoU. Step 2 for UKB employed a Firth penalized regression to variants with a P-value less than 0.05. Reported AoU GWAS summary statistics were filtered for any variant where the MAF x N for the minor allele was less than 20, per the AoU privacy policy. Following GWAS, we determined the HWE MIDP value, using Plink2, for every variant with a p-value $\leq 1 * 10^{-5}$, excluding variants with a MIDP value $\leq 1 * 10^{-15}$, in a single genetic ancestral population, similar to our prior paper[27]. We used a standard p-value threshold

of $5 * 10^{-8}$ as our threshold for genome-wide significance, which accounts for multiple-testing across all independent genetic variants[51].

    While we did not include summary statistics or Manhattan plots for our analyses on AoU participants who self-identified as Hispanic, information on these cohorts is available in our Supplementary materials (**Supplemental Table 1**). As expected, genomic inflation was high in GWAS data focused on AoU participants who self-identified as Hispanic. Inflation in that cohort was greatly improved by including genetic ancestry as a covariate, which motivated this paper's methods.

Meta-analysis.

    Meta-analyzed results were processed using METAL[52] (the most recent version, released on 25 March 2011) using default settings, aside from using inverse standard error values as weights and outputting the average allele frequency across studies. The final results were filtered for genetic variants with a frequency amplitude less than 0.4 (or difference between the maximum and minimum allele frequency between studies[3]), variants that were genome-wide significant, variants that were detected in both the AoU and NIAGADS studies (a degrees of freedom value of 1), and variants that had a HWE p-value larger than $1 * 10^{-15}$ in all AoU ancestry-stratified populations (EUR, AFR, AMR, EAS, SAS, or MID). Following this, we used Plink2 to clump every significant variant by locus in our study using AoU genetic data, using a threshold R^2 of 1%[48]. We used a standard p-value threshold of $5 * 10^{-8}$ as our threshold for genome-wide significance[51].

Variant gene annotations and differential gene expression.

We used FAVOR to obtain the genes proximal to each genetic variant[53]. For variants that passed inclusionary criteria, we then evaluated their cognate gene's differential expression in single brain cells for individuals with and without pathological and clinical features of AD using data from Mathys et al. 2023 using an FDR cutoff of 1%[28]. Their analysis incorporated single-cell sequencing of 2.3 million prefrontal cortex cells from 427 individuals with varying degrees of AD pathology and cognitive impairment. These cells were grouped to form 12 major categories with 54 high-resolution cell types, including excitatory neuron subtypes, inhibitory neuron subtypes, oligodendrocytes, oligodendrocyte precursor cells, astrocyte subtypes, immune cell types, and vascular cell types[28].

Power calculations.

We used the Genetic Association Study Power Calculator, available from the University of Michigan, to calculate power (https://csg.sph.umich.edu/abecasis/gas_power_calculator/). We use case and control counts from our study (**Supplementary Table 1**), a significance level of 5×10^{-8}, an additive disease model, a disease prevalence of 11.1%, and used variant-level information for disease allele frequency and genotype relative risk.

Acknowledgements:

This work was supported by Cure Alzheimer's Fund, the JPB Foundation (RET), and NIGMS T32GM007748 (JW). The All of Us Research Program is supported by the National Institutes of Health, Office of the Director: Regional Medical Centers: 1 OT2

OD026549; 1 OT2 OD026554; 1 OT2 OD026557; 1 OT2 OD026556; 1 OT2 OD026550; 1 OT2 OD 026552; 1 OT2 OD026553; 1 OT2 OD026548; 1 OT2 OD026551; 1 OT2 OD026555; IAA #: AOD 16037; Federally Qualified Health Centers: HHSN 263201600085U; Data and Research Center: 5 U2C OD023196; Biobank: 1 U24 OD023121; The Participant Center: U24 OD023176; Participant Technology Systems Center: 1 U24 OD023163; Communications and Engagement: 3 OT2 OD023205; 3 OT2 OD023206; and Community Partners: 1 OT2 OD025277; 3 OT2 OD025315; 1 OT2 OD025337; 1 OT2 OD025276. In addition, the All of Us Research Program would not be possible without the partnership of its participants. Access to individual-level data from the All of Us research program was obtained through an MGB-signed a data use agreement with All of Us (https:// www.researchallofus.org/register/). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. We value the participants who volunteered for both the UKB and AoU. We appreciate the assistance of Cynthia Morton and James Gusella for providing feedback for this study. The computations in this paper were run in part on the FASRC Cannon cluster supported by the FAS Division of Science Research Computing Group at Harvard University. Please refer to the Supplementary Note for full acknowledgements. Samples, genomic data, and health information for the MGB cohort were obtained from the Mass General Brigham Biobank, a biorepository of consented patients samples at Mass General Brigham (parent organization of Massachusetts General Hospital and Brigham and Women's Hospital). Whole genome library prep and sequencing of samples was performed at the Mass General Brigham Biobank Genomics Core with funding from Cure Alzheimer's Fund.

Author Contributions (CRediT Author Statement).

Julian Willett: conceptualization, methodology, software, validation, formal analysis, investigation, data curation, writing – original draft, writing – review and editing, visualization, supervision. Mohammad Waqas: formal analysis, validation, data curation, writing – review and editing. Serhiy Naumenko: data curation, writing – review and editing. Kristina Mullin: project administration, data curation, writing – review and editing. Julian Hecker: validation, writing – review and editing. Christoph Lange: validation, resources, writing – review and editing. Lars Bertram: validation, writing – review and editing. Winston Hide: validation, data curation, resources, writing – review and editing. Rudolph Tanzi: conceptualization, validation, resources, writing – review and editing, supervision, funding acquisition. Dmitry Prokopenko: conceptualization, methodology, validation, formal analysis, resources, data curation, writing – review and editing, supervision, project administration, funding acquisition.

Data availability.

NIAGADS data access is available through the DSS NIAGADS under accession number: NG00067. The NIAGADS dataset contains data in part obtained from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database (adni.loni.usc.edu). As such, the investigators within the ADNI contributed to the design and implementation of ADNI and/or provided data but did not participate in analysis or writing of this report. UKB data access is available through application at https://ukbiobank.dnanexus.com/landing. Access to individual-level data from the All of Us research program was obtained through an MGB-signed data use agreement with

All of Us (https:// www.researchallofus.org/register/). This research was conducted

using the UKB resource (application number 81874). Full GWAS data for this

manuscript, edited to comply with privacy requirements for AoU, is available by request.

Code availability.

Code is publicly available on Github:

https://github.com/juliandwillett/NIA_AOU_ProjPCs_Study.

References:

1. Hebert, L.E., Weuve, J., Scherr, P.A. & Evans, D.A. Alzheimer disease in the United States (2010-2050) estimated using the 2010 census. *Neurology* **80**, 1778-83 (2013).
2. Andrews, S.J. *et al.* The complex genetic architecture of Alzheimer's disease: novel insights and future directions. *EBioMedicine* **90**, 104511 (2023).
3. Bellenguez, C. *et al.* New insights into the genetic etiology of Alzheimer's disease and related dementias. *Nat Genet* **54**, 412-436 (2022).
4. Vega, I.E., Cabrera, L.Y., Wygant, C.M., Velez-Ortiz, D. & Counts, S.E. Alzheimer's Disease in the Latino Community: Intersection of Genetics and Social Determinants of Health. *J Alzheimers Dis* **58**, 979-992 (2017).
5. Sofer, T. *et al.* A polygenic risk score for Alzheimer's disease constructed using APOE-region variants has stronger association than APOE alleles with mild cognitive impairment in Hispanic/Latino adults in the U.S. *Alzheimers Res Ther* **15**, 146 (2023).
6. Yang, Y. *et al.* Genome-wide association study of mild cognitive impairment in diverse Hispanic/Latinos identifies novel loci and reveals heterogeneous associations across genetic backgrounds. *Alzheimer's & Dementia* **17**(2021).
7. Medicine., N.A.o.S.E.a. Using Population Descriptors in Genetics and Genomics Research: A New Framework for an Evolving Field. (Washington, DC, 2023).
8. Conomos, M.P. *et al.* Genetic Diversity and Association Studies in US Hispanic/Latino Populations: Applications in the Hispanic Community Health Study/Study of Latinos. *Am J Hum Genet* **98**, 165-84 (2016).
9. Adhikari, K., Mendoza-Revilla, J., Chacon-Duque, J.C., Fuentes-Guajardo, M. & Ruiz-Linares, A. Admixture in Latin America. *Curr Opin Genet Dev* **41**, 106-114 (2016).
10. Belbin, G.M., Nieves-Colon, M.A., Kenny, E.E., Moreno-Estrada, A. & Gignoux, C.R. Genetic diversity in populations across Latin America: implications for population and medical genetic studies. *Curr Opin Genet Dev* **53**, 98-104 (2018).
11. Xue, D., Blue, E.E., Conomos, M.P. & Fohner, A.E. The power of representation: Statistical analysis of diversity in US Alzheimer's disease genetics data. *Alzheimers Dement (N Y)* **10**, e12462 (2024).
12. Housini, M. *et al.* Top Alzheimer's disease risk allele frequencies differ in HABS-HD Mexican- versus Non-Hispanic White Americans. *Alzheimers Dement (Amst)* **15**, e12518 (2023).
13. Cheng, R. *et al.* Linkage analysis of multiplex Caribbean Hispanic families loaded for unexplained early-onset cases identifies novel Alzheimer's disease loci. *Alzheimers Dement (Amst)* **10**, 554-562 (2018).
14. Lee, W.P. *et al.* Association of common and rare variants with Alzheimer's disease in more than 13,000 diverse individuals with whole-genome sequencing from the Alzheimer's Disease Sequencing Project. *Alzheimers Dement* **20**, 8470-8483 (2024).
15. Thul, P.J. & Lindskog, C. The human protein atlas: A spatial map of the human proteome. *Protein Sci* **27**, 233-244 (2018).

16. Coste, B. *et al.* Piezo1 and Piezo2 are essential components of distinct mechanically activated cation channels. *Science* **330**, 55-60 (2010).
17. Jantti, H. *et al.* Microglial amyloid beta clearance is driven by PIEZO1 channels. *J Neuroinflammation* **19**, 147 (2022).
18. Radio, F.C. *et al.* SPEN haploinsufficiency causes a neurodevelopmental disorder overlapping proximal 1p36 deletion syndrome with an episignature of X chromosomes in females. *Am J Hum Genet* **108**, 502-516 (2021).
19. Stelzer, G. *et al.* The GeneCards Suite: From Gene Data Mining to Disease Genome Sequence Analyses. *Curr Protoc Bioinformatics* **54**, 1 30 1-1 30 33 (2016).
20. Sollis, E. *et al.* The NHGRI-EBI GWAS Catalog: knowledgebase and deposition resource. *Nucleic Acids Res* **51**, D977-D985 (2023).
21. Morello, G. *et al.* Copy Number Variations in Amyotrophic Lateral Sclerosis: Piecing the Mosaic Tiles Together through a Systems Biology Approach. *Mol Neurobiol* **55**, 1299-1322 (2018).
22. Gouveia, C. *et al.* Genome-wide association of polygenic risk extremes for Alzheimer's disease in the UK Biobank. *Sci Rep* **12**, 8404 (2022).
23. Uffelmann, E., Posthuma, D. & Peyrot, W.J. Genome-wide association studies of polygenic risk score-derived phenotypes may lead to inflated false positive rates. *Sci Rep* **13**, 4219 (2023).
24. Gns, H.S., Rajalekshmi, S.G. & Burri, R.R. Revelation of Pivotal Genes Pertinent to Alzheimer's Pathogenesis: A Methodical Evaluation of 32 GEO Datasets. *J Mol Neurosci* **72**, 303-322 (2022).
25. Breza, M. *et al.* A homozygous GDAP2 loss-of-function variant in a patient with adult-onset cerebellar ataxia. *Brain* **143**, e49 (2020).
26. Ahlers-Dannen, K.E., Spicer, M.M. & Fisher, R.A. RGS Proteins as Critical Regulators of Motor Function and Their Implications in Parkinson's Disease. *Molecular Pharmacology* **98**, 730-738 (2020).
27. Willett, J.D.S. *et al.* Identification of 16 novel Alzheimer's disease susceptibility loci using multi-ancestry meta-analyses of clinical Alzheimer's disease and AD-by-proxy cases from four whole genome sequencing datasets. *medRxiv* (2024).
28. Mathys, H. *et al.* Single-cell atlas reveals correlates of high cognitive function, dementia, and resilience to Alzheimer's disease pathology. *Cell* **186**, 4365-4385 e27 (2023).
29. Petrovic, S. *et al.* Structural remodeling of AAA+ ATPase p97 by adaptor protein ASPL facilitates posttranslational methylation by METTL21D. *Proc Natl Acad Sci U S A* **120**, e2208941120 (2023).
30. Grimaldi, A. *et al.* Inflammation, neurodegeneration and protein aggregation in the retina as ocular biomarkers for Alzheimer's disease in the 3xTg-AD mouse model. *Cell Death Dis* **9**, 685 (2018).
31. Kohler, S. *et al.* The Human Phenotype Ontology in 2017. *Nucleic Acids Res* **45**, D865-D876 (2017).
32. UniProt, C. UniProt: the universal protein knowledgebase in 2021. *Nucleic Acids Res* **49**, D480-D489 (2021).
33. Wu, Y. *et al.* Pervasive biases in proxy genome-wide association studies based on parental history of Alzheimer's disease. *Nat Genet* **56**, 2696-2703 (2024).

34. Liu, J.Z., Erlich, Y. & Pickrell, J.K. Case-control association mapping by proxy using family history of disease. *Nat Genet* **49**, 325-331 (2017).
35. Valero, S. *et al.* Interaction of neuropsychiatric symptoms with APOE epsilon4 and conversion to dementia in MCI patients in a Memory Clinic. *Sci Rep* **10**, 20058 (2020).
36. Gibson, J. *et al.* Assessing the presence of shared genetic architecture between Alzheimer's disease and major depressive disorder using genome-wide association data. *Transl Psychiatry* **7**, e1094 (2017).
37. Leung, Y.Y. *et al.* VCPA: genomic variant calling pipeline and data management tool for Alzheimer's Disease Sequencing Project. *Bioinformatics* **35**, 1768-1770 (2019).
38. All of Us Research Program, I. *et al.* The "All of Us" Research Program. *N Engl J Med* **381**, 668-676 (2019).
39. Ramirez, A.H. *et al.* The All of Us Research Program: Data quality, utility, and diversity. *Patterns* **3**(2022).
40. Boutin, N.T. *et al.* The Evolution of a Large Biobank at Mass General Brigham. *J Pers Med* **12**(2022).
41. Wu, Y. *et al.* Pervasive biases in proxy GWAS based on parental history of Alzheimer's disease. *bioRxiv* (2023).
42. Manichaikul, A. *et al.* Robust relationship inference in genome-wide association studies. *Bioinformatics* **26**, 2867-73 (2010).
43. Prive, F. Using the UK Biobank as a global reference of worldwide populations: application to measuring ancestry diversity from GWAS summary statistics. *Bioinformatics* **38**, 3477-3480 (2022).
44. Wang, X. *et al.* Common and rare variants associated with cardiometabolic traits across 98,622 whole-genome sequences in the All of Us research program. *J Hum Genet* (2023).
45. Mbatchou, J. *et al.* Computationally efficient whole-genome regression for quantitative and binary traits. *Nat Genet* **53**, 1097-1103 (2021).
46. Prive, F., Aschard, H., Ziyatdinov, A. & Blum, M.G.B. Efficient analysis of large-scale genome-wide data with two R packages: bigstatsr and bigsnpr. *Bioinformatics* **34**, 2781-2787 (2018).
47. Zhang, Z. Propensity score method: a non-parametric technique to reduce model dependence. *Ann Transl Med* **5**, 7 (2017).
48. Chang, C.C. *et al.* Second-generation PLINK: rising to the challenge of larger and richer datasets. *Gigascience* **4**, 7 (2015).
49. Prokopenko, D. *et al.* Utilizing the Jaccard index to reveal population stratification in sequencing data: a simulation study and an application to the 1000 Genomes Project. *Bioinformatics* **32**, 1366-72 (2016).
50. Bycroft, C. *et al.* The UK Biobank resource with deep phenotyping and genomic data. *Nature* **562**, 203-209 (2018).
51. Fadista, J., Manning, A.K., Florez, J.C. & Groop, L. The (in)famous GWAS P-value threshold revisited and updated for low-frequency variants. *Eur J Hum Genet* **24**, 1202-5 (2016).
52. Willer, C.J., Li, Y. & Abecasis, G.R. METAL: fast and efficient meta-analysis of genomewide association scans. *Bioinformatics* **26**, 2190-1 (2010).

53. Zhou, H. *et al.* FAVOR: functional annotation of variants online resource and annotator for variation across the human genome. *Nucleic Acids Res* **51**, D1300-D1311 (2023).

Figure 1. Study design. NIAGADS result replication in All of Us (AoU) was accomplished by matching AoU participants to NIAGADS using solely genetically-derived projected principal components (PCs) or PCs, age, and sex.

Figure 2. Cohort demographics for All of Us (AoU) and NIAGADS (NIA) studies. AoU PC Match included AoU participants matched to NIAGADS participants who self-identified as Hispanic (NIA HISP) using the first twenty PCs, obtained by projecting AoU array data onto NIAGADS genetic data. AoU PC/Phen Match included AoU participants matched to NIAGADS participants using the first twenty projected PCs, age, and sex. Matching was accomplished using MatchIt's subclassification method, isolating participants with a minimum weight of 1, matching or exceeding the NIAGADS reference population weight.

Figure 3. Manhattan plots of NIAGADS self-identified Hispanic participants and AoU studies conducted on participants who were matched to these NIAGADS participants using projected PCs, with or without age and sex covariates. The ZFYVE1 locus in (A) corresponds to rare variants proximal to PSEN1.

Table 1. Lead variant statistics for each individual GWAS. AoU Gen P contains p-values for the AoU GWAS produced by matching AoU participants to NIAGADS participants who self-identified as Hispanic using solely the projected genetic PCs, with AoU GenPhen P produced by matching with PCs, age, and sex. While none of the AoU lead variants were nominal in the NIAGADS Hispanic participant GWAS, several of the loci contained non-lead variants that were.

CHR	Rsid	Gene	MAF	EA	OR	CI	Direction (by study)	NIA_P	AoU Gen P	AoU GenPhen P	NewOld
NIAGADS Hispanic Participants											
14	rs182804071	ZFYVE1	0.003348	C	9.67	(4.71,19.88)	+--	6.66E-10	0.32096	0.586355	Old
18	rs4573993	PIEZO2	0.352204	A	0.81	(0.75,0.87)	--+	5.38E-08	0.549527	0.84777	New
19	rs429358	APOE	0.145014	C	2.03	(1.84,2.24)	+++	3.18E-46	0.000731	2.31E-07	Old
AoU Participants Matched by Genetic PCs											
1	rs1015482461	SPEN	0.007729	T	3.04	(2.11,4.38)	?++	ND	2.51E-09	3.08E-09	New
1	rs985256115	LINC01364	0.000737	G	15.95	(6.06,41.96)	-++	0.84	1.99E-08	2.43E-05	New
1	rs1225279127	RNA5SP533	0.015632	A	2.4	(1.87,3.09)	?++	ND	1.07E-11	2.22E-11	New
5	rs1298939524	SAR1B	0.007502	AGGCG	2.98	(2.03,4.39)	?++	ND	3.02E-08	0.000166	New
11	rs2120001636	OR4A5, TRIM48	0.008545	C	3.57	(2.53,5.05)	?++	ND	5.12E-13	2.24E-15	New
17	rs1241129008	RN7SL33P, PAFAH1B1	0.003075	G	4.47	(2.66,7.51)	?++	ND	1.61E-08	0.000521	New
17	rs1416175390	UNK	0.004567	A	3.61	(2.31,5.65)	?++	ND	1.76E-08	5.8E-06	New
20	rs1034010324	EPB41L1	0.002942	A	4.82	(2.85,8.17)	-++	0.466226	5.03E-09	7.03E-07	New
AoU Participants Matched by Genetic PCs, Age, and Sex											
1	rs1015482461	SPEN	0.006765	T	3.63	(2.37,5.56)	?++	ND	2.51E-09	3.08E-09	New
1	rs903391718	MACF1	0.0021	A	8.3	(3.89,17.72)	?++	ND	0.00011	4.62E-08	New
1	rs1225279127	RNA5SP533	0.01418	A	2.65	(1.99,3.52)	?++	ND	1.07E-11	2.22E-11	New
1	rs889400412	RALGPS2	0.001118	T	20.62	(7.28,58.37)	+++	0.57669	0.000605	1.2E-08	New
11	rs2120001636	OR4A5, TRIM48	0.006947	C	5.3	(3.51,8)	?++	ND	5.12E-13	2.24E-15	New

Figure 4. Manhattan plots for meta-analyses of NIAGADS participants who self-identified as Hispanic and matched All of Us cohorts, filtered for variants that occurred in both datasets.

Table 2. Lead variant statistics for each meta-analysis. Gen represents AoU participants matched to NIAGADS participants who self-identified as Hispanic using projected principal components. GenPhen represents AoU participants matched by these projected genetic PCs, age, and sex. Direction solely refers to the NIAGADS, AoU matched by genetic principal components, and AoU matched by genetic principal components and phenotypic traits.

CHR	Rsid	Gene	MAF	EA	OR	CI	Direction (by study)	Meta Gen P	Meta GenPhen P	NIA P	AoU Gen P	AoU GenPhen P	NewOld
NIAGADS HISP and AoU Participants Matched by Genetic PCs													
14	rs374043832	RGS6/PSEN1	0.002	A	5.4	(3.0,9.8)	+++	3.08E-08	4.84E-08	4.86E-08	0.050	0.09	Old
17	rs192423465	ASPSCR1	0.003	T	3.3	(2.2,5.0)	+++	1.52E-08	4.2E-05	8.3E-3	1.95E-07	0.001	New
19	rs429358	APOE	0.137	C	1.6	(1.5,1.7)	+++	1.54E-36	2.36E-44	3.2E-46	0.000731	2.31E-07	Old
20	rs1034010324	EPB41L1	0.003	A	4.4	(2.6,7.5)	-++	1.85E-08	2.39E-06	0.47	5.03E-09	7.03E-07	New
NIAGADS HISP and AoU Participants Matched by Genetic PCs, Age, and Sex													
1	rs935208076	RF00561, GDAP2	0.001	C	8.1	(3.9,17.0)	+++	1.98E-06	2.37E-08	0.000882	0.000674	1.82E-06	New
14	rs374043832	RGS6/PSEN1	0.002	A	5.5	(3.0,10.2)	+++	3.08E-08	4.84E-08	4.86E-08	0.051	0.088255	Old
19	rs429358	APOE	0.137	C	1.7	(1.6,1.8)	+++	1.54E-36	2.36E-44	3.18E-46	0.000731	2.31E-07	Old

Table 3. Differential gene expression for meta-analysis loci that were nominally significant in AoU and NIAGADS by presence of cognitive impairment or pathological evidence of disease. Exc represents excitatory neurons. Group comparisons (n v m) include group 1 (no AD pathological evidence or cognitive impairment), group 2 (no pathological evidence with cognitive impairment), group 3 (pathological evidence without cognitive impairment), group 4 (pathological evidence and cognitive impairment). Scores (xN) represent the number of unique cell subpopulations enriched for the cognate gene. Plus and minus signs correspond to whether the log-fold change was positive or negative for the comparison.

CHR	Rsid	Gene	MAF	Cell
17	rs192423465	ASPSCR1	0.0026	(ASPSCR1) Exc 4v1 (x4) ---- (ASPSCR1) Exc 4v3 (x1) -
1	rs935208076	RF00561, GDAP2	0.0011	(GDAP2) Exc 3v1 (x2) ++ (GDAP2) Exc 4v1 (x1) +

Table 4. Differential gene expression for meta-analysis loci that were nominally significant in AoU and NIAGADS, by severity of cognitive impairment and specific pathological hallmarks of disease. For progression-relevant outcomes, amyloid represents amyloid burden, Gpath global AD pathology, NFT neurofibrillary tangle burden, Plaq D diffuse plaque burden, Plaq N neuritic plaque burden, tangles tangle density. For cells, Exc represents excitatory neurons, Inh inhibitory neurons, Oli oligodendrocytes, Ast astrocytes, 2v1 represents comparison of gene expression between individuals with mild cognitive impairment to those with no cognitive impairment, 3v2 comparing individuals with AD dementia and mild cognitive impairment. Scores represent the number of unique cell subpopulations enriched for the cognate gene with signs representing the direction of change in expression in each subpopulation.

Path	CHR	Rsid	Gene	MAF	Cell
Plaq_D	17	rs192423465	ASPSCR1	0.0026	(ASPSCR1) Exc 2v1 (x1) -
NFT	17	rs192423465	ASPSCR1	0.0026	(ASPSCR1) Exc 3v2 (x2) -- (ASPSCR1) Inh 3v2 (x2) --
Amyloid	17	rs192423465	ASPSCR1	0.0026	(ASPSCR1) Exc 2v1 (x8) -------- (ASPSCR1) Inh 2v1 (x2) --
Gpath	17	rs192423465	ASPSCR1	0.0026	(ASPSCR1) Exc 2v1 (x1) - (ASPSCR1) Exc 3v2 (x1) -
Plaq_N	17	rs192423465	ASPSCR1	0.0026	(ASPSCR1) Exc 2v1 (x6) ------ (ASPSCR1) Exc 3v2 (x1) + (ASPSCR1) Inh 2v1 (x3) ---
Tangles	17	rs192423465	ASPSCR1	0.0026	(ASPSCR1) Exc 3v2 (x2) -- (ASPSCR1) Inh 3v2 (x1) -
Plaq_D	1	rs935208076	RF00561, GDAP2	0.0011	(GDAP2) Exc 3v2 (x4) ++++
NFT	1	rs935208076	RF00561, GDAP2	0.0011	(GDAP2) Exc 2v1 (x1) +
Amyloid	1	rs935208076	RF00561, GDAP2	0.0011	(GDAP2) Exc 2v1 (x6) ++++++ (GDAP2) Inh 2v1 (x2) ++ (GDAP2) Mic 2v1 (x1) +
Gpath	1	rs935208076	RF00561, GDAP2	0.0011	(GDAP2) Exc 2v1 (x7) +++++++ (GDAP2) Inh 2v1 (x1) + (GDAP2) Oli 2v1 (x1) + (GDAP2) Ast 2v1 (x1) + (GDAP2) Ast 3v2 (x1) -
Plaq_N	1	rs935208076	RF00561, GDAP2	0.0011	(GDAP2) Exc 2v1 (x3) +++
Tangles	1	rs935208076	RF00561, GDAP2	0.0011	(GDAP2) Exc 2v1 (x5) +++++
Plaq_D	1	rs935208076	RF00561, GDAP2	0.0011	(GDAP2) Exc 3v2 (x4) ++++

Supplemental Table 1. Demographic information for each cohort in our study. Single ancestral population percentages represent the proportion of the total sample size composed of the indicated ancestral population.

Cohort	NIAGADS Hispanic	AoU Matched by Gen PCs	AoU Matched by Gen PCs, Age, and Sex	AoU Hispanic
Outcome	Clinical AD	AD-by-proxy	AD-by-proxy	AD-by-proxy
Cases	2,559	9,479	4,633	1,695
Controls	5,908	35,314	20,869	54,868
Total Sample Size	8,467	44,793	25,502	56,563
Case Percentage	30.2%	21.2%	18.2%	3.0%
African Ancestry	1,528 (18.0%), 628 Cases	2,130 (4.8%), 996 Cases	3,175 (12.5%), 615 Cases	5,650 (10.0%), 85 Cases
Admixed-American Ancestry	1,356 (16.0%), 264 Cases	32,855 (73.3%), 1,100 Cases	15,674 (61.5%), 767 Cases	43,328 (76.6%), 1,056 Cases
European Ancestry	3,721 (43.9%), 1,402 Cases	7,142 (15.9%), 7,077 Cases	5,174 (20.3%), 3,097 Cases	7,042 (12.4%), 538 Cases
Asian (East or South) Ancestry	2,065 (24.4%), 329 Cases	2,551 (5.7%), 285 Cases	1,431 (5.6%), 146 Cases	485 (0.9%), 14 Cases
Middle-Eastern Ancestry	NA	115 (0.3%), 21 Cases	48 (0.2%), 8 Cases	58 (0.1%), 2 Cases
Age: Mean (SD)	71.7 (9.6)	50.2 (16.4)	67.9 (13.4)	50.2 (16.3)
Female Sex Percentage	67.2%	66.5%	66.0%	62.1%
rs429358 MAF (ApoE4)	14.5%	12.8%	12.8%	12.8%
rs7412 MAF (ApoE2)	4.2%	4.9%	5.6%	5.3%

A. NIAGADS HISP

B. AoU Matched using Genetic PCs

C. AoU Matched using Genetic PCs, Age, and Sex

D. Meta-analysis of NIAGADS HISP and AoU Matched using Genetic PCs

E. Meta-analysis of NIAGADS HISP and AoU Matched using Genetic PCs, Age, and Sex

Supplemental Figure 1. QQ plots, with genomic inflation factor, for each dataset.

Supplemental Figure 2. Principal component plots for each dataset.